Estrogens, Conjugated (USP). Carentil . Climarest . Climopax . Congest . Conjugated Equine Estrogens . Conjugated Estrogens . Dagynil . Estro-Feminal . Estrogenic Hormones, Conjugated . Estrogens, Conjugated . Femavit . Oestro-Feminal . Oestrofeminal . Prelestrin . Premarin . Presomen . Progens . Transannon . Conjugated Estrogenic Hormones . Conjugated Estrogenic Substances . Equine Estrogens, Conjugated . Estro Feminal . Oestro Feminal . Estrogenic Substances, Conjugated . Conjugated Estrogens . Estrogenic Hormones, Conjugated . Estrogens, Conjugated . A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate. . 0.50
Agouti Signaling Protein. ASIP Protein . Agouti Protein . Agouti Switch Protein . A secreted protein of approximately 131 amino acids (depending on species) that regulates the synthesis of eumelanin (brown/black) pigments in MELANOCYTES. Agouti protein antagonizes the signaling of MELANOCORTIN RECEPTORS and has wide distribution including ADIPOSE TISSUE; GONADS; and HEART. Its overexpression in agouti mice results in uniform yellow coat color, OBESITY, and metabolic defects similar to type II diabetes in humans. . 0.47
Tacrolimus. Anhydrous Tacrolimus . FK-506 . FK506 . FR-900506 . Prograf . Prograft . Tacrolimus Anhydrous . Anhydrous, Tacrolimus . FK 506 . FR 900506 . FR900506 . Tacrolimus, Anhydrous . A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro. . 0.46
Progeria. Hutchinson Gilford Progeria Syndrome . Hutchinson-Gilford Progeria Syndrome . Hutchinson Gilford Syndrome . Hutchinson-Gilford Progeria Syndromes . Progeria Syndrome, Hutchinson-Gilford . Progeria Syndromes, Hutchinson-Gilford . Hutchinson-Gilford Syndrome . An abnormal congenital condition, associated with defects in the LAMIN TYPE A gene, which is characterized by premature aging in children, where all the changes of cell senescence occur. It is manifested by premature greying; hair loss; hearing loss (DEAFNESS); cataracts (CATARACT); ARTHRITIS; OSTEOPOROSIS; DIABETES MELLITUS; atrophy of subcutaneous fat; skeletal hypoplasia; elevated urinary HYALURONIC ACID; and accelerated ATHEROSCLEROSIS. Many affected individuals develop malignant tumors, especially SARCOMA. . 0.45
Programs. Programs [Publication Type] . Works consisting of lists of the events, pieces, performers, speakers, etc., of an entertainment, ceremony, or the like. (From: Genre Terms: A Thesaurus for Use in Rare Book and Special Collections Cataloging, 2d ed) . 0.43
0
0
Chondrocalcinosis. Calcium Pyrophosphate Deposition Disease . Chondrocalcinoses . Pseudogout . Calcium Pyrophosphate Dihydrate Deposition . Presence of CALCIUM PYROPHOSPHATE in the connective tissues such as the cartilaginous structures of joints. When accompanied by GOUT-like symptoms, it is referred to as pseudogout. . 0.42
